Open AccessEfficacy of nilotinib therapy in patient with CML diagnosed in pre-TKI era and resistant to imatinib
Author(s) -
Ivana Pierri,
Micaela Bergamaschi,
Antonia Cagnetta,
Anna Ghiso,
Marco Gobbi
Publication year - 2015
Publication title -
clinical management issues
Language(s) - English
Resource type - Journals
eISSN - 2283-3137
pISSN - 1973-4832
DOI - 10.7175/cmi.v4i6s.1100
Subject(s) - medicine , nilotinib , imatinib , chronic myeloid leukaemia , tyrosine kinase inhibitor , tyrosine kinase , oncology , surgery , myeloid leukemia , cancer , receptor
Here we report a case of a 32-year-old man, who was diagnosed as having chronic myeloid leukaemia in 1998. After cytoreduction with hydroxyurea, the patient was submitted to high dose chemotherapy with haemopoietic stem cells rescue and reinfusion, and then he started therapy with IFNα without achievement of a cytogenetic response. On November 2000 he took imatinib 400 mg/day and he reached a complete cytogenetic response (CCyR) at 14 months, but not the major molecular response: therefore he was considered a sub-optimal responder according to European LeukemiaNet criteria of 2006. For this reason he increased imatinib dose to 800 mg/day, but after one year he lost CCyR. Considering the patient as a failure, at this time, he switched to second-generation tyrosine kinase inhibitor, nilotinib at the dose of 800 mg/day. After 3 months he reached complete CCyR and after 6 months the major molecular response, maintained until last molecular evaluation.